U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932809) titled 'Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A' on April 10.
Brief Summary: The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and ...